News

  • All
  • Company News
  • Nirogy News
  • Press Releases
All
  • All
  • Company News
  • Nirogy News
  • Press Releases
Press Releases

Nirogy Therapeutics to Present at AACR Annual Meeting 2022

Two posters highlighting preclinical data of a small molecule development candidate with a novel mechanism of immune activation in the TME and cancer cell intrinsic …

Read More →
Company News

Nirogy Therapeutics Presented at Keystone Symposia on Cancer Immunotherapy: Decoding the Cancer Immunity Interactome. British Columbia, CANADA

Framingham, MA, March 30, 2022, Nirogy Therapeutics, a biopharmaceutical company focused on oncology and Immune diseases, presented at the Cancer Immunotherapy: Decoding the cancer immunity …

Read More →
Company News

Nirogy Therapeutics Appoints Simon Pedder, Ph.D., as Chief Executive Officer

Appointment Strengthens Leadership and Expertise to Drive Lead Oncology Program into Phase 1 Clinical Development Founding Chief Executive Officer Dr. Vincent Sandanayaka transitions to role …

Read More →
Company News

Nirogy Therapeutics Opens New Lab and Office Space as Headquarters Near Boston to Expand Operations

BOSTON, July 15, 2021 – Nirogy Therapeutics Inc., a privately-held biotechnology company developing novel small molecules to target cellular transporters, today announced the opening of …

Read More →
Press Releases

Nirogy Therapeutics to Present at AACR Annual Meeting 2021

E-posters highlighting preclinical data demonstrate the potential of Nirogy’s small molecule therapies to enable significant activation of anti-tumor immunity and simultaneous killing of cancer cells …

Read More →
Nirogy News

Market ‘Solutes’ Nirogy Small-Molecule Flag with $16.5M Series A

Boston-based Nirogy Therapeutics Inc.’s $16.5 million series A round is meant to enable a pipeline of small-molecule drugs targeting the solute carrier family of transporter …

Read More →
Scroll to Top

This website uses cookies to ensure you get the best experience on our website.

Vincent P. Sandanayaka, Ph.D.

FOUNDER

At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt mollitia animi, id est laborum et dolorum fuga. Et harum quidem rerum facilis est et expedita distinctio. Nam libero tempore, cum soluta nobis est eligendi optio cumque nihil impedit quo minus id quod maxime placeat facere possimus, omnis voluptas assumenda est, omnis dolor repellendus. Temporibus autem quibusdam et aut officiis debitis aut rerum necessitatibus saepe eveniet ut et voluptates repudiandae sint et molestiae non recusandae. Itaque earum rerum hic tenetur a sapiente delectus, ut aut reiciendis voluptatibus maiores alias consequatur aut perferendis doloribus asperiores repellat